ESMO Preceptorship on Metastatic Bladder and Kidney Cancer 2019: Singapore
![ESMO Preceptorship Metastatic Bladder and Kidney Cancer Singapore 2019](/var/esmo/storage/images/media/esmo/meetings/2019/preceptorships-2019/esmo-preceptorship-metastatic-bladder-and-kidney-cancer-singapore-2019/3588347-3-eng-GB/esmo-preceptorship-metastatic-bladder-and-kidney-cancer-singapore-2019.jpg)
- Start date
- 04 Sep 2019
- End date
- 05 Sep 2019
- Location
- Republic of Singapore
Learning objectives
- To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
- To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
- To learn about advances in treatment and novel targets in bladder and kidney cancer
Accreditation
The programme of this event has been accredited with 8 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Co-Chairs
- Ravindran Kanesvaran, Singapore
- Naveen Vasudev, United Kingdom